Special lssues

Technologies and development of rare disease diagnosis

  • WANG Yuanpin ,
  • HU Xiaomin ,
  • GONG Mengchun ,
  • LING Chao
  • 1. Rare Disease Research Center, Chinese Academy of Medical Sciences, Beijing 100730, China;
    2. Central Research Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;
    3. Genetics Research Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Received date: 2017-05-25

  Revised date: 2017-07-31

  Online published: 2017-08-26


Most of rare diseases are hereditary diseases, characterized by low incidence, numerous varieties and diverse phenotypes, and therefore it is difficult to diagnose rare diseases timely and accurately in clinical practice. With the advances in the molecular genetics, the molecular diagnostic techniques, and the gene sequencing and omics techniques, a significant progress has been made in the diagnosis of rare diseases in recent years. On the basis of traditional gene detection techniques, the next-generation sequencing technology has been rapidly developed and widely used in the diagnosis and the research of rare diseases. The next-generation sequencing technology is costeffective and of high capacity over the traditional gene tests, and is well developed for the clinical use. The third generation sequencing also shows a potential diagnostic value. Although the traditional enzymatic detection techniques play an important role in the diagnosis of rare diseases, they fail to meet the surging diagnostic demands. Studies demonstrate that the rise of the proteomics and the metabolomics enables an accurate diagnosis of a variety of rare diseases. The computer-assisted initial diagnosis also sees a bright future, combined with the molecular imaging and the bio-information technologies. Technological advances have enhanced the ability to diagnose rare diseases to a great extent.

Cite this article

WANG Yuanpin , HU Xiaomin , GONG Mengchun , LING Chao . Technologies and development of rare disease diagnosis[J]. Science & Technology Review, 2017 , 35(16) : 26 -30 . DOI: 10.3981/j.issn.1000-7857.2017.16.003


[1] Rath A, Olry A, Dhombres F, et al. Representation of rare diseases in health information systems:The orphanet approach to serve a wide range of end users[J]. Human Mutation, 2012, 33(5):803-808.
[2] Anderson M, Elliott E J, Zurynski Y A. Australian families living with rare disease:Experiences of diagnosis, health services use and needs for psychosocial support[J]. Orphanet Journal of Rare Diseases, 2013, 8:22.
[3] Amberger J S, Bocchini C A, Schiettecatte F, et al. OMIM.org:Online mendelian inheritance in man (OMIM(R)), an online catalog of human genes and genetic disorders[J]. Nucleic Acids Research, 2015, 43(Data-base issue):D789-D798.
[4] Cui Y, Han J. Defining rare diseases in China[J]. Intractable and Rare Diseases Research, 2017, 6(2):148-149.
[5] Wang J B, Guo J J, Yang L, et al. Rare diseases and legislation in Chi-na[J]. Lancet, 2010, 375(9716):708-709.
[6] Korf B R, Rehm H L. New approaches to molecular diagnosis[J]. Jour-nal of the American Medical Association, 2013, 309(14):1511-1521.
[7] Sanger F, Nicklen S, Coulson A R. DNA sequencing with chain-termi-nating inhibitors[J]. Proceedings of the National Academy of Sciences, 1977, 74(12):5463-5467.
[8] Genomes P C, Abecasis G R, Auton A, et al. An integrated map of ge-netic variation from 1092 human genomes[J]. Nature, 2012, 491(7422):56-65.
[9] van Dijk E L, Auger H, Jaszczyszyn Y, et al. Ten years of next-genera-tion sequencing technology[J]. Trends in Genetics, 2014, 30(9):418-426.
[10] Danielsson K, Mun L J, Lordemann A, et al. Next-generation sequenc-ing applied to rare diseases genomics[J]. Expert Review of Molecuar Diagnosis, 2014, 14(4):469-487.
[11] Nguyen M T, Charlebois K. The clinical utility of whole-exome se-quencing in the context of rare diseases-the changing tides of medical practice[J]. Clinical Genetics, 2015, 88(4):313-319.
[12] Stark Z, Tan T Y, Chong B, et al. A prospective evaluation of wholeexome sequencing as a first-tier molecular test in infants with suspect-ed monogenic disorders[J]. Genetics in Medicine, 2016, 18(11):1090-1096.
[13] Brown T L, Meloche T M. Exome sequencing a review of new strate-gies for rare genomic disease research[J]. Genomics, 2016, 108(3-4):109-114.
[14] Meynert A M, Ansari M, FitzPatrick D R, et al. Variant detection sen-sitivity and biases in whole genome and exome sequencing[J]. BMC Bioinformatics, 2014, 15:247.
[15] Aparisi M J, Aller E, Fuster-Garcia C, et al. Targeted next generation sequencing for molecular diagnosis of Usher syndrome[J]. Orphanet Journal of Rare Diseases, 2014, 9:168.
[16] Duan S, Mi S, Zhang W, et al. Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes[J]. RNA Biology, 2009, 6(4):412-425.
[17] Salvatore M, Magrelli A, Taruscio D. The role of microRNAs in the bi-ology of rare diseases[J]. International Journal of Molecuar Sciences, 2011, 12(10):6733-6742.
[18] Riedmaier I, Pfaffl M W. Transcriptional biomarkers-high throughput screening, quantitative verification, and bioinformatical validation methods[J]. Methods, 2013, 59(1):3-9.
[19] Wang Y, Yang Q, Wang Z. The evolution of nanopore sequencing[J]. Frontiers in Genetics, 2014, 5:449.
[20] Quick J, Loman N J, Duraffour S, et al. Real-time, portable genome sequencing for Ebola surveillance[J]. Nature, 2016, 530(7589):228-232.
[21] Lu H, Giordano F, Ning Z. Oxford nanopore MinION sequencing and genome assembly[J]. Genomics Proteomics Bioinformatics, 2016, 14(5):265-279.
[22] Roos D, de Boer M. Molecular diagnosis of chronic granulomatous dis-ease[J]. Clinical and Experimental Immunology, 2014, 175(2):139-149.
[23] Csorba K, Schmidt S, Florea F, et al. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases[J]. Orphanet Journal of Rare Diseases, 2011, 6(1):31.
[24] Gulbakan B, Ozgul R K, Yuzbasioglu A, et al. Discovery of biomark-ers in rare diseases:innovative approaches by predictive and personal-ized medicine[J]. EPMA Journal, 2016, 7(1):24.
[25] Royal V, Quint P, Leblanc M, et al. IgD heavy-chain deposition dis-ease:detection by laser microdissection and mass spectrometry[J]. Journal of American Society of Nephrology, 2015, 26(4):784-790.
[26] Ayoglu B, Chaouch A, Lochmuller H, et al. Affinity proteomics within rare diseases:a BIO-NMD study for blood biomarkers of muscular dystrophies[J]. EMBO Molecular Medicine, 2014, 6(7):918-936.
[27] Norman R, Haas M, Wilcken B. International perspectives on the costeffectiveness of tandem mass spectrometry for rare metabolic condi-tions[J]. Health Policy, 2009, 89(3):252-260.
[28] Piras D, Locci E, Palmas F, et al. Rare disease:a focus on metabolo-mics[J]. Expert Opinion on Orphan Drugs, 2016, 4(12):1229-1237.
[29] Bekiesinska-Figatowska M. Imaging in the diagnosis of rare diseases[J]. Developmental Period Medicine, 2015,19(4):407-412.
[30] Alves R, Pinol M, Vilaplana J, et al. Computer-assisted initial diagno-sis of rare diseases[J]. PeerJ, 2016, 4(Suppl 1):e2211.